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Duplex ultrasound imaging alone is sufficient for
midterm endovascular aneurysm repair
surveillance: A cost analysis study and prospective
comparison with computed tomography scan
Brian R. Beeman, MD, Lynne M. Doctor, BA, Kevin Doerr, RVT, Sandy McAfee-Bennett, RVT,
Matthew J. Dougherty, MD, and Keith D. Calligaro, MD, Philadelphia, Pa
Objective: Early in our experience with endovascular aortic aneurysm repair (EVAR) we performed both serial computed
tomography scans and duplex ultrasound (DU) imaging in our post-EVAR surveillance regimen. Later we conducted a
prospective study with DU imaging as the sole surveillance study and determined cost savings and outcome using this
strategy.
Methods: From September 21, 1998, to May 30, 2008, 250 patients underwent EVAR at our hospital. Before July 1,
2004, EVAR patients underwent CT and DU imaging performed every 6 months during the first year and then annually
if no problems were identified (group 1). We compared aneurysm sac size, presence of endoleak, and graft patency
between the two scanning modalities. After July 1, 2004, patients underwent surveillance using DU imaging as the sole
surveillance study unless a problemwas detected (group 2). CT andDU imaging charges for each regimen were compared
using our 2008 health system pricing and Medicare reimbursements. All DU examinations were performed in our
accredited noninvasive vascular laboratory by experienced technologists. Statistical analysis was performed using Pearson
correlation coefficient.
Results: DU and CT scans were equivalent in determining aneurysm sac diameter after EVAR (P < .001). DU and CT
were each as likely to falsely suggest an endoleak when none existed and were as likely to miss an endoleak. Using DU
imaging alone would have reduced cost of EVAR surveillance by 29% ($534,356) in group 1. Cost savings of $1595 per
patient per year were realized in group 2 by eliminating CT scan surveillance. None of the group 2 patients sustained an
adverse event such as rupture, graft migration, or limb occlusion as a result of having DU imaging performed as the sole
follow-up modality.
Conclusion: Surveillance of EVAR patients can be performed accurately, safely, and cost-effectively with DU as the sole
imaging study. (J Vasc Surg 2009;50:1019-24.)Despite many clinical benefits and widespread use,
enthusiasm for endovascular abdominal aneurysm repair
(EVAR) has been tempered by long-term concerns. To
date, computed tomography (CT) has been the preferred
modality to detect EVAR-related complications such as
migration, endoleak, and stent graft thrombosis.1 The rec-
ommended practice of performing CT scans at 1, 6, and 12
months, and annually thereafter is included in the instruc-
tions for all marketed devices, which were carried through
from regulatory trials.2 Limited data have been published
concerning the efficacy of this regimen.
The need for lifelong surveillance for potential compli-
cations has also called into question the cost-effectiveness
of EVAR.3-8 A recent study reported that65% of postop-
erative EVAR costs are due to CT scanning alone.9 Medi-
care reimbursement often fails to meet hospital costs of
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doi:10.1016/j.jvs.2009.06.019EVAR.4 Hospitals and health care systems, already faced
with escalating costs, may find that financial considerations
will influence use of EVAR. Although CT remains the most
commonly used modality for post-EVAR surveillance, cost
is not the only drawback. Radiation exposure after repeated
examinations is a significant consideration.10 Contrast ne-
phropathy and allergy are another concern: contrast ne-
phropathy affects 7% to 12% of patients after CT angio-
graphy.11,12
For these reasons, alternative surveillance methods,
such as duplex ultrasound (DU) imaging, have been ex-
plored. Recent studies have confirmed that DU surveillance
is a safe and effective modality for analyzing infrarenal
abdominal aortic aneurysm (AAA) sac dimensions, en-
doleak detection, and graft patency.1,13-17
Because of the disadvantages of CT scans and our
confidence in our noninvasive vascular laboratory, we be-
gan to prospectively use DU as the sole imaging study after
EVAR, aside from a single CT scan in the immediate
postoperative period. We analyzed AAA sac diameter, pres-
ence of endoleak, and graft patency, and compared the
utility of using DU scanning alone vs both DU and CT
scanning as surveillance tools. In addition, we performed a
cost analysis for the two different protocols.
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From September 21, 1998, to May 30, 2008, 250
patients underwent EVAR on the vascular surgery service at
Pennsylvania Hospital in Philadelphia. Five types of en-
dografts were used during this time-period: Ancure (Endo-
vascular Technologies, Menlo Park, Calif) early in our
experience and later AneuRx (Medtronic, Minneapolis,
Minn), Excluder (W.L. Gore and Associates Inc, Flagstaff,
Ariz), Zenith (Cook Medical Inc, Bloomington, Ind), and
Powerlink (Endologix, Irvine, Calif).
The original surveillance protocol was modeled from
that suggested by EVAR regulatory trials, registries, and
device manufacturers.2 Before July 1, 2004, our protocol
consisted of CT and DU scanning 2 weeks of discharge,
at 6 and 12 months, and then yearly (group 1). After this
date, we obtained one CT and DU scan 2 weeks of
surgery and then performed DU examinations at 6 and 12
months and then yearly if no problems were detected
(group 2). Some patients had CT scans at other institutions
besides ours and were included in the analysis, but all
patients in this series had follow-up DU scans performed in
our vascular laboratory in Philadelphia or at a satellite office
in southern New Jersey by the same technologists. If CT or
DU suggested an endoleak, an expanding AAA sac diame-
ter, or a significant stenosis in the limb of a graft, more
frequent or invasive studies and intervention were done
when necessary.
All patients were included in a prospectively maintained
computerized registry (Access, Microsoft Corp, Redmond,
Wash). Hospital, office, and noninvasive vascular labora-
tory records were reviewed to determine AAA post-EVAR
sac diameters, endoleak rate, and graft patency. Graft limb
stenosis was defined as stenosis or kinking based on a focal
elevated peak systolic velocity three times higher than the
normal adjacent site.
A true-positive study was defined as one where con-
comitant (performed1month of each other) CT andDU
examinations confirmed an endoleak or graft stenosis or
where concomitant studies disagreed but subsequent CT,
DU scans, or arteriography during follow-up confirmed the
abnormality found on the original study. A false-positive
study was defined as a study that suggested a problem that
was discordant with the concomitant alternative study, and
with subsequent CT, DU imaging, or arteriography not
confirming the problem. A false-negative study was one in
which the imaging study missed a problem but other con-
comitant or subsequent studies confirmed an abnormality.
Questionable findings were those in which a problem was
identified by one study but no other studies were per-
formed1month to confirm or contradict the finding, and
no subsequent studies were performed. False-positive and
false-negative statistics were compared with the Fischer
exact test, with P  .05 considered significant.
CT scanning was performed using a standardized en-
dograft protocol with delayed dual spiral imaging before
and after (60- and 120-second delays) administration of a
175- to 200-mL bolus of intravenous contrast. Multipleaxial images were taken using 2-mm slices with a 1.5-mm
reconstruction algorithm throughout the abdomen and
pelvis.
DU examination was performed in our accredited vas-
cular laboratory (International Committee of Accredited
Vascular Laboratory) by one of three certified technolo-
gists. DU imaging equipment equipped with 10.4 software
did not change over the study period (Philips HD-11,
Philips HDI-5000, Philips HDI-3000; Bothell, Wash).
During DU examinations, the aorta was scanned in long-
axis and in cross-sectional views from the diaphragm dis-
tally to the common femoral arteries. Residual aneurysm
sac diameter was measured. Arterial flow hemodynamics
were documented throughout the endograft using spectral
Doppler velocity measurements. Color Doppler imaging
was adjusted for optimum sensitivity for lower velocities.
The entire endograft and aneurysm sac were scanned to
detect any endoleaks. Endoleaks were classified as occur-
ring at the proximal or distal attachment sites (type I), at
graft module junctions (type III), or secondary to patent
aortic branch vessels (type II), such as the inferior mesen-
teric artery or lumbar arteries, which demonstrated collat-
eral filling and back-bleeding into the aneurysm sac. Pres-
ence or absence of endoleaks by DU imaging was based
primarily on real-time B-mode image data with spectral
Doppler recordings.
CT and DU measurements of AAA sac diameter were
compared using the Pearson correlation coefficient, with
P  .05 considered significant. All statistical analysis was
performed using SPSS software (SPSS Inc, Chicago, Ill).
Charges for CT and DU EVAR surveillance were com-
pared using 2008 health system charges and 2008 Medi-
care reimbursements. Our health system charges for a com-
plete CT scan with EVAR protocol included abdominal
($4052) and pelvic ($4052) views for a total charge of
$8104. Our health system charges for aortic DU EVAR
protocols were $360 per study. Medicare reimbursements
were $949 for a complete CT scan with EVAR protocol and
$232 for a DU study.
RESULTS
Of the 250 patients who underwent EVAR during the
study period, 51 were excluded from analysis primarily
because our noninvasive vascular laboratory was not able to
perform surveillance DU studies due to incompatibility
with third-party payer reimbursements, inadequate follow-
up intervals, or data points were insufficient to make
meaningful comparisons. The remaining 199 patients com-
prised group 1 (82 patients) and group 2 (117 patients).
The average age of patients was 73 years (range, 63-82
years), and 80% were men. The average diameter of the
AAAs treated with EVAR was 5.8 cm (range, 4.4-9.7 cm).
AneuRx (Medtronic, Minneapolis, Minn) grafts were the
most commonly placed endografts in our series (36%;
Table I). Very rarely we needed to performCT scans instead
of DU imaging for extremely obese patients, but these
patients were not included in this report.
n, and
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endoleaks. Four patients, two in each group, had both type
I and type II endoleaks, there were eight type I endoleaks (5
in group 1, 3 in group 2), and 46 type II endoleaks (18 in
group 1, 28 in group 2). There were 16 endoleaks (6 in
group 1, 10 in group 2) detected using one imaging
modality that were not confirmed by the other study 1
month or because the other modality was not performed at
all. The primary reason for lack of confirmatory studies
were findings of small type II endoleaks documented by the
DU examination without apparent sac expansion. In these
circumstances, CT scans were not obtained because no
action would likely be taken. Of the 21 endoleaks found in
the operating room and at the immediate postoperative CT
scan, three resolved by 3 months, one by 6 months, and
four by 9 months. Four patients were lost to follow-up by 9
months, leaving nine of 21 endoleaks that persisted at 9
months after EVAR.
An endoleak was missed in 16 patients who had false-
negative scans: eight in group 1 (2 DU, 6 CT) and eight in
group 2 (3 DU, 5 CT; Table II). Most of these patients had
type II endoleaks that did not require intervention. A single
type I endoleak was missed by CT scan but found by DU
imaging in group 1, which subsequently required an exten-
sion cuff. The false-negative rate for CT scans was 5.5% (11
of 199), and the false-negative rate for DU studies was 2.5%
(5 of 199; P  .126). Thus, there was no significant
difference in false-negative scans by CT and DU, although
Table I. Demographics and devices used for group 1 and
an endoleak
Variable a
Group 1 (n  82)
No endoleak Endoleak
Age, y 72.71  7.35 74.14  6.81
Sex, male 46 (80.70) 22 (84.62)
Aneurysm size, cm 5.8  0.84 6.0  1.07
Device
AneuRx 15 (26.79) 11 (40.74)
Excluder 8 (14.29) 2 (7.41)
Cook 9 (16.07) 4 (14.81)
Ancure 24 (42.86) 10 (37.04)
Endologix 0 (0.00) 0 (0.00)
aAge and aneurysm sac size are presented as an average with standard deviatio
Table II. Patients with false-negative (endoleak was
missed) and false-positive (endoleak detected when none
existed) detection of endoleak by computed tomography
or duplex ultrasound imaging
Modality
False – False 
No. (%) No. (%)
Computed tomography 11 (5.5) 2 (1.0)
Duplex ultrasound 5 (2.5) 5 (2.5)
Total 16 (8.0) 7 (3.5)a trend existed favoring DU imaging.A false-positive examination suggested an endoleak
when none existed in seven patients, five in group 1 (4 DU,
1 CT) and two in group 2 (1 DU, 1 CT). Most of the
results suggested type II endoleaks, but concomitant stud-
ies did not confirm the findings. One type I endoleak was
suggested by DU imaging and subsequently ruled out by
aortogram; thus, the false-positive rate was 1.0% (2 of 199)
for CT and 2.5% (5 of 199) for DU imaging (P  .253),
which was not significantly different (Table II). DU sensi-
tivity for detecting endoleak was 0.710 and specificity was
0.990, whereas CT sensitivity was 0.731 and specificity was
0.991.
In addition, six possible endoleaks (1 in group 1 and 5
in group 2) were detected by one modality but were not
confirmed by subsequent DU scans or CT. The group 1
patient was lost to follow-up; the group 2 patients had small
type II endoleaks on DU imaging with no CT performed.
In group 1, 23 endoleaks were demonstrated in 21 of
82 patients (26%) during follow-up: five type I and 18 type
II (2 patients had both types I and II). Overall, 10 of the 21
patients (48%) with endoleaks in group 1 underwent surveil-
lance without intervention and 11 (52%) required endovascu-
lar intervention, comprising seven cuffs or extension limbs to
treat type I endoleaks and six coil embolizations to seal type II
endoleaks.
In group 2, 31 endoleaks were demonstrated in 29 of
117 patients (25%): 3 type I and 28 type II (2 patients had
both types I and II). Overall, 26 of 29 patients (90%) with
endoleaks in group 2 underwent surveillance without inter-
vention and three (10%) required endovascular interven-
tion, which consisted of one percutaneous balloon angio-
plasty of a previously placed proximal cuff to treat a type I
endoleak and one coil embolization to seal a type II en-
doleak. One patient in group 2 who had a type I endoleak
was not treated due to a recent diagnosis of advanced
cancer. No patients in either group experienced a ruptured
aneurysm after EVAR during the follow-up period.
Surveillance of graft patency using CT andDU imaging
was also compared. For the 199 patients in this study, limb
migrations or stenosis occurred in seven (4%) that threat-
p 2, broken down into patients with and without
Group 2 (n  117)
Total (n  199)No endoleak Endoleak
71.91  8.59 75.10  7.68 72.93  7.93
63 (77.78) 29 (80.56) 160 (80.00)
5.7  1.22 6.0  1.26 5.8  1.11
31 (38.27) 14 (38.89) 71 (35.50)
15 (18.52) 8 (22.22) 33 (16.50)
29 (35.80) 14 (38.89) 56 (28.00)
0 (0.00) 0 (0.00) 34 (17.00)
6 (74.10) 0 (0.00) 6 (3.00)
sex and device type are shown as number and percentage of the total group.grouened overall endograft patency. Two graft migrations (both
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(true-positive examinations) and treated with extension
cuffs.18 Five limb stenoses or kinks were identified, one by
both CT and DU findings and the other four by DU stud-
ies only. Although DU imaging identified these graft-
threatening lesions, which were later successfully treated,
these studies were not confirmed or refuted by concomitant
imaging studies 1 month, but instead four of the five
lesions underwent elective intervention. The operative
findings confirmed the DU findings in all cases. Of these
five patients, two were treated with femoral-femoral by-
passes, two with balloon angioplasty with stenting, and one
with axillary-femoral bypass. The five limbs identified as
failing grafts due to stenosis or kinks had peak systolic
velocities of 308, 399, 515, 521, and 530 cm/s. These five
endograft limbs were two AneuRx, two Ancure, and one
Zenith. Four of the five limbs underwent prophylactic
intervention, but one graft limb in a high-surgical-risk
patient was initially observed. This graft later occluded and
thrombosed, resulting in severe ischemia that required
urgent intervention. No aneurysm-related deaths occurred
during the follow-up, but two patients died secondary to
myocardial infarction.
Aneurysm sac diameters after EVAR were compared
between DU and CT studies that were performed 1
month of each other in group 1. Available for comparison
were 114 data points from 75 patients in group 1 (Fig 1). A
statistically significant Pearson correlation coefficient of
0.956 (P  .001) was established showing DU and CT
Fig 1. Diameters of aneurysm sacs during surveillance after endo-
vascular abdominal aortic aneurysm (AAA) repair are shown in
114 data points from 75 patients comparing computed tomogra-
phy (CT, y axis) and duplex ultrasound (DU; x-axis) scans per-
formed 1 month of each other. The Pearson correlation coeffi-
cient was 0.956, which was statistically significant (P  .001).provided similar findings. Therefore, DU imaging in ourstudy predicted aneurysm sac diameters as precisely as CT,
and could be reliably used to determine whether to inter-
vene based on expanding sac size.
Average follow-up with graft surveillance in group 1
patients after EVAR was 3.5 years (range, 0-9 years). Hos-
pital system charges for surveillance studies in group 1
patients, which included 204 CT scans and 550 DU stud-
ies, were $1,851,216. Medicare reimbursement for these
studies was $321,196. Average follow-upwith graft surveil-
lance in our more recently enrolled patients in group 2
was 1.6 years (range, 6 months-4 years). Hospital system
charges for surveillance studies for group 2 patients, which
included 102 CT scans and 390 DU studies, were
$967,008. Medicare charges for group 2 patients were
$187,278. Had DU alone been used for graft surveillance
of group 1, charges for EVAR surveillance would have been
reduced by $534,356 and Medicare reimbursements by
$66,163. Charges per patient (y axis) for each year after
EVAR (x axis) for group 1 patients were compared with
group 2 patients (Fig 2). Charges are high for group 1
patients receiving both CT and DU scans, particularly in
the early follow-up period. Decreased charges of $1595 per
patient per year or $198 per patient per year usingMedicare
reimbursements were realized by eliminating CT scan sur-
veillance in group 2. The payor mix for our patients in-
cluded private insurance, 55%; Medicare, 31%; Medicaid,
8%; and patient pay, 6%.
DISCUSSION
Although previous authors have compared DU and CT
scans for surveillance after EVAR, CT scan remains the gold
standard to assess aneurysm diameter, presence of en-
doleak, and graft patency.13-17,19 The benefits of CT as an
imaging modality compared with DU imaging include that
Fig 2. Follow-up charges for group 1 (black bars) and group 2
(gray bars) are compared based on 2008 health care system pricing
(y axis) per patient for each year of follow-up (x axis) after endo-
vascular aneurysm repair and are not cumulative.it is highly reproducible, less influenced by body habitus,
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limitations of CT scans are repeated radiation exposure,
potential contrast-related complications, including allergy
and renal insufficiency, and high costs.
We have shown that cost savings is substantial when
DU imaging alone is used for midterm follow-up vs the
accepted approach that requires multiple CT scans. Ben-
dick et al16 reported that eliminating CT as a surveillance
tool after EVAR would represent a 3-year cost savings of
$16,000 per patient.16 In fact, new surveillance para-
digms have already been suggested to reduce the charges
associated with EVAR, and to our knowledge, ours is the
first prospective study comparing the different surveillance
regimens.19 Kim et al20 estimated that current reimburse-
ment for long-term EVAR surveillance and secondary pro-
cedures using traditional protocols average a net loss of
$2235 per patient.
Although hospital system charges vary by institution,
Medicare reimbursement schedules are fixed and often
used as a benchmark for private insurance payors to deter-
mine what a fair market value should be for an imaging
study. Reimbursement is not always at the Medicare level
and can influence charges. Cumulative reimbursement for
the hospital will be less if our protocol is followed, because
fewer CT scans will be performed and hospital administra-
tors may not favor this cost-saving strategy.
Inflation and decreasing reimbursements over time af-
fect cost and charges, which makes a true cost analysis
difficult. We performed our cost analysis using 2008 health
care system charges to reflect the potential cost savings for
the current economic climate and with today’s health care
system, which is significantly different than that of 1998,
when our study began. Regardless, the cost savings are
substantial when CT and DU are compared for EVAR
surveillance.
AAA size reduction over time has been used as a
surrogate marker for successful exclusion, thrombosis of
the aneurysm sac, and decreased risk of rupture.21 We
showed that CT and DU imaging were equivalent for
measuring AAA sac size after EVAR (Fig 1). This finding
reassured us that DU imaging alone could potentially serve
as the only surveillance study for EVAR patients, at least in
terms of identifying sac expansion.
Endoleak detection by DU imaging was as or more
accurate than by CT because the false-negative rate for DU
was 2.5% compared with 5.5% for CT. The five false-
negative DU examinations were not vascular technologist-
dependent. Aneurysm sac remodeling may explain why
these five endoleaks were detected by DU imaging later
during follow-up and not initially by CT, given that sac
diameter in each case had changed by at least 0.5 cm in size.
Perhaps with aneurysm sac remodeling, back bleeding ves-
sels become more readily apparent. DU imaging may ulti-
mately prove to be more sensitive than CT in detecting
endoleaks given its ability to detect subtle flow characteris-
tics within an aneurysm sac. Our technologists were able to
document flow velocities in these endoleaks. Arko et al22reported that intrasac DU flow velocities may help inpredicting whether type II endoleaks will seal spontane-
ously and therefore not require intervention, suggesting a
peak systolic velocity of80 cm/s as being safe. When type
II endoleak peak systolic velocities are elevated 80 cm/s,
we recommend more frequent DU follow-up.
When there is any question of sac expansion, or for
persistent type II endoleaks with elevated velocities, we
would recommend performing CT angiography. Our
follow-up in group 2 patients was limited and does not
reflect 3-year follow-up, when increasing risk of endoleak
may occur. CT requires multiple scans at different contrast
times to detect endoleaks and cannot predict which en-
doleaks will regress. Currently, sac pressure sensors are still
largely experimental and confined to a few centers experi-
enced with this technique.23 Nonetheless, pressure sensors
in the sac may prove more accurate and useful than CT or
DU scanning in the future.24,25
We believe that DU imaging is more accurate than CT
in detecting problems that threaten graft patency, such as
migration, kinking, and stenosis. Color-flow images give
physiologic as well as anatomic information that CT does
not. DU imaging accurately predicted all seven cases where
graft patency appeared threatened. The ability to quantify
and compare serial examinations in a cost-effective,
contrast-free, and radiation-safe manner suggests that DU
imaging should be the gold standard for EVAR limb patency
follow-up. In our opinion, use of plain x-ray films of the
abdomen may be an outdated method to detect endograft
problems. We believe that DU imaging can almost always
accurately determine if structural defects are causing a flow-
related problem and graft migration.
This study has some potential weaknesses. DU imaging
is more operator-dependent than CT and is significantly
affected by the patient’s body habitus and fasting status.
DU imaging with contrast may prove to be especially useful
for obese patients but is not necessarily any better in most
patients, especially considering the extra cost and more
difficult technique required to use this method.14,16
Interobserver variability in technical factors can be an-
other important limitation in the diagnostic value of DU
imaging.26 Several reports have shown that DU measure-
ments of AAA diameter vary greatly compared with CT; in
our vascular laboratory, they did not. We believe each
vascular laboratory needs to do its own comparison of CT
and DU imaging to determine accuracy.
The safety of DU imaging in post-EVAR surveillance
should be tested in one’s own noninvasive vascular labora-
tory before it is adopted as the sole study to make clinical
decisions about patients after EVAR. There is a possibility
that as more AAAs with shorter necks are treated, our
findings showing the safety and efficacy of using DU imag-
ing alone to monitor EVARs may be affected. If we were
particularly concerned about short infrarenal aortic necks,
we would recommend more frequent follow-up with DU
and possibly CT angiography to better define the anatomy.
The accuracy of DU imaging to detect endoleak or
limb stenosis may vary depending on different graft de-
signs; however, in our experience, other secondary inter-
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branches have more of an effect on the accuracy of DU
imaging than the graft design. Our results were obtained by
experienced, technically superb vascular technologists, and
less experienced or skilled technologists may not achieve
the same results.
CONCLUSION
The search for the optimal means of surveillance for
complications of EVAR continues to evolve. CT and DU
imaging can both detect AAA sac dimensions, endoleaks,
and graft patency. The cost difference between the two
imaging techniques is substantial. Our results demonstrate
that DU surveillance during midterm follow-up after
EVAR performed in an experienced vascular laboratory can
accurately detect aneurysm size, endoleaks, and stenotic or
kinked graft limbs while lowering the overall costs of sur-
veillance. We do not advocate eliminating CT completely
from surveillance protocols but would limit its use to those
circumstances in which it could provide other details about
problems first detected by the DU examination.
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